The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.
This type of tracking helps a practice understand how radiologists interact with AI, whether they're appropriately rejecting incorrect results, and if the technology is improving detection of important findings.
Tim Szczykutowicz, PhD, associate professor radiology, University of Wisconsin Madison, explains the new technology developments in GE HealthCare's FDA 510(k)-pending photon-counting CT scanner.
Intravascular lithotripsy is expected to see even wider adoption when lower-profile catheters are introduced and device costs start to drop, explained Samin Sharma, MD.
J.D. Corl, MD, shared his experience using two new IVL catheters from Shockwave Medical to treat patients with heavily calcified peripheral arteries. He considers both new devices a significant upgrade.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."
Sanjit S. Jolly, MD, MSc, reviewed his team's late-breaking data on treating heart attack patients with colchicine. "I think inflammation is an important area, but I don't think colchicine is the magic bullet," he said.
Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, discussed how a proactive treatment strategy for patients with asymptomatic AS can lead to better outcomes and improvements in quality of life.
Harlan Krumholz, MD, editor-in-chief of the Journal of the American College of Cardiology, said tricuspid valve treatments are a popular topic among cardiologists right now. TAVR research, meanwhile, remains as important as ever.
The Medical Group Management Association (MGMA) Senior Vice of Government Affairs, Anders Gilberg, explains MGMA’s 28-page letter to CMS on issues with the proposed 2025 Medicare Physician Fee Schedule.
